Autologous stem cell therapy - CellPraxis/Cryopraxis

Drug Profile

Autologous stem cell therapy - CellPraxis/Cryopraxis

Alternative Names: MonoCell; ReACT; Refractory angina cell therapy

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CellPraxis; Cryopraxis
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Angina pectoris

Most Recent Events

  • 13 Aug 2015 No recent reports on development identified - Phase-II for Angina pectoris (Treatment-experienced) in Brazil (Intracardiac)
  • 06 Nov 2012 Cryopraxis and CellPraxis plan a Phase-III trial for Angina pectoris (treatment-experienced patients) in Brazil
  • 31 Dec 2011 Cryopraxis and CellPraxis complete a Phase-II trial in Angina pectoris (treatment-experienced patients) in Brazil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top